Financial performance and economic value added: the case of a pharmaceutical company
Purpose: To analyze leading Mexican pharmaceutical company Genomma Lab's financial performance by examining its value creation from 2010 to 2020. Method: A case study approach is employed, incorporating an analysis of Porter's Five Forces, the calculation of Economic Value Added (EVA) alo...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universidad de Concepción
2025-07-01
|
| Series: | RAN |
| Subjects: | |
| Online Access: | https://revistas.udec.cl/index.php/ran/article/view/14293 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Purpose: To analyze leading Mexican pharmaceutical company Genomma Lab's financial performance by examining its value creation from 2010 to 2020.
Method: A case study approach is employed, incorporating an analysis of Porter's Five Forces, the calculation of Economic Value Added (EVA) alongside traditional financial indicators, and a longitudinal and correlational analysis of the relationships among these metrics.
Findings: The firm presented value creation from 2010 to 2014, value destruction in 2015 and 2016, and value creation again from 2017 to 2020. ROA and EVA show a moderate positive correlation; ROE and EVA, a high positive correlation; and a very high positive correlation between EVA and EPS. In contrast, while the ROCE metric showed no correlation.
Practical Implications: The Economic Value-Added model can be applied to Latin American companies to complement traditional methods of analysis of financial performance.
Originality: This study contributes to the literature on financial performance measurement through the implementation of the Economic Value-Added model in the Latin American context. Additionally, it contributes to the comparison of traditional metrics, a topic that has been under-researched. |
|---|---|
| ISSN: | 0719-7713 0719-6245 |